Radionuclide Therapy of Bone Metastases

Area of Science:

• Oncology
• Nuclear Medicine
• Radiopharmacology

Background:

• Bone metastases are a common complication of advanced cancers, particularly prostate and breast cancer, leading to significant pain.
• Osteoblastic bone lesions and associated pain syndromes necessitate effective palliative treatments.

Purpose of the Study:

• To evaluate the efficacy of radionuclide therapy for pain palliation in patients with bone metastases.
• To assess the safety and repeatability of radionuclide therapy.
• To explore novel therapeutic strategies combining radionuclides with chemotherapy.

Main Methods:

• Administration of low-energy beta-emitting radionuclides, specifically (153)samarium-ethylenediaminetetramethylenephosphonate (EDTMP) and (89)strontium.
• Targeted delivery of radiation to bone metastases and bone marrow micrometastases.
• Monitoring of pain syndrome response and patient cell counts for therapy repeatability.

Main Results:

• Radionuclide therapy achieved a pain syndrome response rate of approximately 75%.
• About 25% of patients experienced complete pain remission.
• The therapy is repeatable and can be safely combined with bisphosphonates.

Conclusions:

• Low-energy beta-emitting radionuclides are effective for palliative treatment of bone pain in cancer patients with bone metastases.
• Repeatable administration and compatibility with bisphosphonates enhance therapeutic utility.
• Emerging research with (223)Radium and combination therapies shows promise for more curative outcomes.